TB-500: What the Research Looks At
Updated 2026-09-03
An education-first look at TB-500: what it is, how it is studied, and its current US regulatory status. Not medical advice.
What it is
TB-500 is the name most commonly used online for a synthetic peptide described as a fragment or analog of Thymosin Beta-4, a small protein that occurs naturally in nearly every human and animal cell and plays a role in actin binding and cell movement. It is not an approved pharmaceutical drug, and it is not permitted as an ingredient in dietary supplements sold at retail in the United States. TB-500 is most often discussed online in the context of connective-tissue and recovery research, a framing that comes largely from animal and laboratory studies rather than from any approved human indication. Because products sold online under the "TB-500" name are not standardized, purity and identity cannot be assumed without independent lab testing.
How it is studied
Research connected to Thymosin Beta-4 and TB-500-labeled peptides is concentrated in rodent and cell-culture models, examining tendon, muscle, and soft-tissue models along with actin-related cell signaling. A search of the PubMed database shows this research dates back several decades and spans multiple labs internationally, though direct, controlled human clinical trial data specific to injectable TB-500 remains scarce as of this update. Where small human case series or observational reports exist, researchers who publish in this space describe the evidence as preliminary and call for larger, controlled studies before any conclusions can be drawn. Dose amounts reported in animal studies are specific to those study protocols and are not a guide for human use.
What the research looks at
The available literature has explored Thymosin Beta-4 and related fragments in connection with tendon and ligament injury models, cell migration, and some cardiovascular and inflammatory markers in animals. Researchers frame these as areas of ongoing investigation rather than established outcomes in people. Extrapolating from animal-only data to human use carries real limitations, since dosing, absorption, and metabolism can differ meaningfully between species. That gap is one reason no regulatory body has moved to approve TB-500 for a human indication.
Regulatory status
TB-500 has not been approved by the FDA for any use, and it is not classified as a
dietary supplement ingredient. Peptides in this general category, including several used
in sports-recovery and biohacking contexts, have drawn scrutiny from FDA compounding
policy reviews over the past several years, and 503A and 503B compounding rules for
research-only peptides can change without much public notice (see
/regulation/fda-category-2-list-explained/ and
/regulation/503a-vs-503b-compounding-explained/). Because the FDA's bulk substance lists
are updated periodically, readers should check the current
/regulation/fda-compounding-rulings-2026-update/ page rather than assume a fixed status.
TB-500 also appears on anti-doping prohibited-substance frameworks maintained by bodies
such as WADA under growth factor and peptide categories, which is a separate matter from
its FDA compounding status and relevant to any competitive athlete considering it (see
/regulation/wada-prohibited-list-peptides/).
Safety signals reported
Independent, controlled human safety data on TB-500 is limited, in large part because few controlled human trials have been published. Reports circulating in online communities are largely anecdotal and are not a substitute for peer-reviewed safety data. Unregulated, unverified sourcing is itself a safety consideration: products purchased outside a licensed pharmacy channel have no independent confirmation that they match their labeled contents, purity, or sterility. Anyone with an active cancer diagnosis, anyone who is pregnant or breastfeeding, and anyone on blood-thinning medication should raise those factors explicitly with a provider before considering any unapproved peptide. This is not medical advice. Discuss any decision about a research or compounded substance with a licensed healthcare provider first.
Questions to ask a clinician
- What published human evidence, if any, exists for a substance like this?
- Is this compoundable in this state right now, and from what type of licensed pharmacy?
- How would you verify the purity and identity of a product before I considered it?
- What are the known interaction risks with any medications or conditions I already have?
- If I compete in a sport with anti-doping testing, what should I know before considering this?
FAQ
Is TB-500 the same thing as Thymosin Beta-4? TB-500 is typically described as a synthetic fragment or analog of Thymosin Beta-4, a naturally occurring protein involved in actin regulation and cell movement. Manufacturers and researchers do not always use the terms interchangeably, and product purity and identity are not independently verified outside a lab setting.
Is TB-500 legal to buy in the United States? TB-500 is not approved by the FDA for any human use. Compounding pharmacy reviews in recent years have raised safety-data concerns about several research peptides in this category, and FDA policy in this area has changed more than once, so readers should check the agency's current compounding substance lists rather than assume a fixed status.
Has TB-500 been tested in humans? Published human trial data is limited. Most available research comes from animal and cell-culture models, and researchers who work in this area routinely describe the human evidence base as preliminary.
Why is TB-500 discussed in sports and fitness communities? Interest largely traces back to animal studies on tissue and connective-tissue models plus anecdotal reports from athletes and biohackers. Anecdote is not clinical evidence, and TB-500 also appears on anti-doping prohibited-substance lists, which is a separate consideration from its research status.
Sources
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503B -- https://www.fda.gov/drugs/human-drug-compounding/fda-issues-list-bulk-drug-substances-outsourcing-facilities-may-use-compound-under-section-503b
- World Anti-Doping Agency, Prohibited List -- https://www.wada-ama.org/en/prohibited-list
- PubMed, search results for "thymosin beta-4 peptide" -- https://pubmed.ncbi.nlm.nih.gov/?term=thymosin+beta-4+peptide
Disclaimer
This content is for general education only and is not medical advice, diagnosis, or treatment. Peptide Briefs does not sell peptides and does not recommend any specific product, dose, or protocol. These statements have not been evaluated by the Food and Drug Administration. Always talk with a licensed healthcare provider before starting, stopping, or changing any therapy.